Transvaginal Low-level Laser Therapy to Improve Pelvic Pain and Sexual Function in Patients with Endometriosis.
Key facts
- Who runs it
- Medstar Health Research Institute
- Where
- McLean, Mitchellville, Rockville, and Washington D.C., United StatesSee the 6 sites
- Trial code
- Status
- Terminated
- People taking part
- 6 people enrolled
- Started
- 2 May 2023
- Ended
- 1 Jul 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Transvaginal photobiomodulation
- Sham therapy
- Record updated
- 19 February 2025
- Why it stopped
- Study unable to be conducted with resources at site.
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Proficient English-speaking females
- Pathology proven endometriosis, >6 weeks from prior pelvic surgery
- Current dyspareunia
Who cannot take part
- Currently taking light-sensitizing drugs
- History of or active treatment for pelvic malignancy
- Unable to comply with study protocol
- Pregnant or attempting to become pregnant
Where in United States
- MedStar McLean ClinicMcLean, United States
- MedStar Mitchellville ClinicMitchellville, United States
- MedStar Rockville ClinicRockville, United States
- MedStar Georgetown University HospitalWashington D.C., United States
- MedStar Lafayette CenterWashington D.C., United States
- MedStar Washington Hospital CenterWashington D.C., United States
About the trial
What the trial wants to find out
Dyspareunia is defined as pain with penetrative sexual intercourse. Women with endometriosis have a nine-fold increased risk of dyspareunia, when compared to the general female population.
Read full original descriptionShow less
A prospective single-blinded randomized controlled trial will be performed evaluating the change in pelvic pain and sexual satisfaction scores from baseline to 6 weeks after treatment with transvaginal photobiomodulation therapy or sham therapy. Treatment will involve 9 planned treatment sessions over 3-4 weeks. 40 women will be included in the study.
The 2 groups in the trial
- Transvaginal photobiomodulationExisting treatment, for comparison
Participants will undergo active transvaginal photobiomodulation therapy per clinic protocol, using the SoLa Pelvic Therapy system. This includes 9 treatments, each lasting about 3-5 minutes. A sterile narrow vaginal probe is inserted into the vagina, the low-level laser is activated, and the probe is slowly moved along the vaginal walls for the indicated period of time, via a surface area power calculation based on the measured vaginal length at the beginning of the procedure. The 9 treatments must be completed in 3-4 weeks. Intervention: Active SoLa Low-level laser therapy
- Sham treatmentSham treatment, for comparison
Participants will undergo sham transvaginal photobiomodulation therapy, following the same protocol as the active arm, without activation of the machine. This includes 9 treatments, lasting 3-5 minutes each. A sterile narrow vaginal probe is inserted into the vagina, the machine is NOT activated, and the inactive probe is slowly moved along the vaginal walls for 3-5 minutes. The 9 treatments must be completed in 3-4 weeks. Intervention: Mock treatment with inactivated probe
Treatment: Sham therapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Transvaginal Photobiomodulation for the Treatment of Dyspareunia in Endometriosis Patients: a Randomized Controlled Trial
- Record updated
- 19 February 2025